Published in Proc Natl Acad Sci U S A on March 01, 1975
Interaction of hyperthermia and the hypoxic cell sensitizer Ro-07-0582 on the EMT6 mouse tumour. Br J Cancer (1977) 1.90
Studies with bleomycin and misonidazole on aerated and hypoxic cells. Br J Cancer (1978) 1.61
Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl Oncol (2008) 1.51
Temperature and host defense. Microbiol Rev (1979) 1.35
Hyperthermia and human leukocyte functions: effects on response of lymphocytes to mitogen and antigen and bactericidal capacity of monocytes and neutrophils. Infect Immun (1977) 1.20
Photothermally enhanced drug delivery by ultrasmall multifunctional FeCo/graphitic shell nanocrystals. ACS Nano (2011) 1.13
The sensitivity to cytotoxic agents of the EMT6 tumor in vivo. Comparative response of lung nodules in rapid expotential growth and of the solid flank tumour. Br J Cancer (1976) 1.12
A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia (2010) 1.04
Synergistic effects of cisplatin chemotherapy and gold nanorod-mediated hyperthermia on ovarian cancer cells and tumors. Nanomedicine (Lond) (2014) 0.96
Three-dimensional imaging of single nanotube molecule endocytosis on plasmonic substrates. Nat Commun (2012) 0.93
Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer (1994) 0.93
A comparison of the response to hyperthermia of murine haemopoietic stem cells (CFU-S) and L1210 leukaemia cells: enhanced killing of leukaemic cells in presence of normal marrow cells. Br J Cancer (1981) 0.89
Using pharmacologic data to plan clinical treatments for patients with peritoneal surface malignancy. Curr Drug Discov Technol (2009) 0.88
Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol (2015) 0.88
Thermal targeting of an acid-sensitive doxorubicin conjugate of elastin-like polypeptide enhances the therapeutic efficacy compared with the parent compound in vivo. Mol Cancer Ther (2012) 0.87
Gold nanoshelled liquid perfluorocarbon magnetic nanocapsules: a nanotheranostic platform for bimodal ultrasound/magnetic resonance imaging guided photothermal tumor ablation. Theranostics (2013) 0.87
Sound waves and antineoplastic drugs: The possibility of an enhanced combined anticancer therapy. J Med Ultrason (2001) (2002) 0.86
Pharmacologic rationale for treatments of peritoneal surface malignancy from colorectal cancer. World J Gastrointest Oncol (2010) 0.83
Nanoshell-mediated photothermal therapy can enhance chemotherapy in inflammatory breast cancer cells. Int J Nanomedicine (2015) 0.82
Multifunctional superparamagnetic iron oxide nanoparticles for combined chemotherapy and hyperthermia cancer treatment. Nanoscale (2015) 0.81
Interaction of bleomycin, hyperthermia and a calmodulin inhibitor (trifluoperazine) in mouse tumour cells: I. In vitro cytotoxicity. Br J Cancer (1986) 0.81
Photodynamic hyperthermal chemotherapy with indocyanine green: a novel cancer therapy for 16 cases of malignant soft tissue sarcoma. J Vet Sci (2013) 0.81
Magnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer. Int J Hyperthermia (2010) 0.81
Sequence dependence of the hyperthermic potentiation of carboplatin-induced cytotoxicity and intracellular platinum accumulation in HeLa cells. Br J Cancer (1993) 0.80
Multimodality treatment strategies have changed prognosis of peritoneal metastases. World J Gastrointest Oncol (2016) 0.79
Response of EMT6 multicellular tumour spheroids to hyperthermia and cytotoxic drugs. Br J Cancer (1981) 0.78
Enhancement of adriamycin-induced killing after delayed plating of plateau-phase V79-cells. Br J Cancer (1986) 0.78
Photothermal enhancement of chemotherapy mediated by gold-silica nanoshell-loaded macrophages: in vitro squamous cell carcinoma study. J Biomed Opt (2016) 0.77
Pharmacokinetic study of perioperative intravenous Ifosfamide. Int J Surg Oncol (2011) 0.77
Preloading of Hydrophobic Anticancer Drug into Multifunctional Nanocarrier for Multimodal Imaging, NIR-Responsive Drug Release, and Synergistic Therapy. Small (2016) 0.76
Enhancement of thermal killing by polyamines V. The response of EMT6 multicellular tumour spheroids versus monolayer cells. Br J Cancer (1983) 0.75
Gold nanoparticle-mediated photothermal therapy: applications and opportunities for multimodal cancer treatment. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2017) 0.75
Review: the role of hyperthermia in treating pancreatic tumors. Indian J Surg Oncol (2014) 0.75
Synergistic chemotherapy by combined moderate hyperthermia and photochemical internalization. Biomed Opt Express (2016) 0.75
New advances in surgical oncology. West J Med (1983) 0.75
Does the mode of heat induction modify drug anti-tumour effects? Br J Cancer Suppl (1982) 0.75
Mesoporous carbon nanoshells for high hydrophobic drug loading, multimodal optical imaging, controlled drug release, and synergistic therapy. Nanoscale (2017) 0.75
Chitosan-Gated Magnetic-Responsive Nanocarrier for Dual-Modal Optical Imaging, Switchable Drug Release, and Synergistic Therapy. Adv Healthc Mater (2017) 0.75
Use of methotrexate, vinblastine, adriamycin, and cisplatin in combination with radiation and hyperthermia as neo-adjuvant therapy for bladder cancer. Cancer Chemother Pharmacol (1992) 0.75
Molecular motion in spin-labeled phospholipids and membranes. J Am Chem Soc (1971) 7.23
New antibiotics, bleomycin A and B. J Antibiot (Tokyo) (1966) 3.58
Selective heat sensitivity of cancer cells. Biochemical and clinical studies. Cancer (1967) 3.04
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
Response of solid tumor cells exposed to chemotherapeutic agents in vivo: cell survival after 2- and 24-hour exposure. J Natl Cancer Inst (1973) 1.64
Metabolic aspects of the role of hyperthermia im mammalian cell inactivation and their possible relevance to cancer treatment. Cancer Res (1974) 1.62
Cell survival and repair of plateau-phase cultures after chemotherapy--relevance to tumor therapy and to the in vitro screening of new agents. Cancer Chemother Rep (1974) 1.53
Thermal enhancement of thio-TEPA cytotoxicity. J Natl Cancer Inst (1973) 1.33
Chromosome aberrations induced by thymidine. Exp Cell Res (1966) 1.27
Cellular radiosensitivity and tumor radiation response in the EMT6 tumor cell system. Radiat Res (1973) 1.25
Effect of bleomycin on mammalian cell survival. J Natl Cancer Inst (1972) 1.24
Selective lethal effect of supranormal temperatures on mouse sarcoma cells. Cancer Res (1973) 1.03
Daunomycin metabolism in rat tissue slices. J Pharmacol Exp Ther (1970) 0.99
Adriamycin (14-hydroxydaunomycin), a novel antitumor antibiotic. Tetrahedron Lett (1969) 0.97
Chinese hamster cell monolayer cultures. I. Changes in cell dynamics and modifications of the cell cycle with the period of growth. Exp Cell Res (1968) 0.93
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum (2000) 4.62
The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis (2009) 4.37
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology (2000) 3.90
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 3.17
Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis (2009) 3.15
Blindsight in normal observers. Nature (1995) 3.07
Neuronal activity in human primary visual cortex correlates with perception during binocular rivalry. Nat Neurosci (2000) 2.91
Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum (2003) 2.91
How to diagnose axial spondyloarthritis early. Ann Rheum Dis (2004) 2.91
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Ankylosing spondylitis: an overview. Ann Rheum Dis (2002) 2.71
Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut (2000) 2.71
Results of provider self-adjudication using the prudent layperson standard compared with the managed care organization's emergency department claim review process. Ann Emerg Med (2000) 2.64
Two distinct mechanisms for redistribution of lymphocyte surface macromolecules. I. Relationship to cytoplasmic myosin. J Cell Biol (1978) 2.54
Disability and handicap in rheumatoid arthritis and ankylosing spondylitis--results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol (2000) 2.45
Repair of potentially lethal radiation damage in vitro and in vivo. Radiology (1973) 2.43
Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology (1998) 2.38
ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis (2008) 2.37
HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene. Lancet (1998) 2.32
Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis (2004) 2.26
Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry (1992) 2.19
Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science (1993) 2.08
Attention activates winner-take-all competition among visual filters. Nat Neurosci (1999) 2.04
[The diagnosis of reactive arthritis. The possibilities and limits]. Dtsch Med Wochenschr (1993) 2.03
Plateau-phase cultures of mammalian cells: an in vitro model for human cancer. Curr Top Radiat Res Q (1972) 2.02
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol (2012) 1.91
Selectivity for polar, hyperbolic, and Cartesian gratings in macaque visual cortex. Science (1993) 1.88
Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis (2000) 1.85
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis (2013) 1.81
CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J Clin Endocrinol Metab (1997) 1.78
[Amendment of the structural quality for inpatient rheumatology. A forward-looking concept]. Z Rheumatol (2011) 1.74
Nonspecific stabilization of stress-susceptible proteins by stress-resistant proteins: a model for the biological role of heat shock proteins. Proc Natl Acad Sci U S A (1982) 1.73
Ethanol-induced tolerance to heat and to adriamycin. Nature (1978) 1.70
Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis (2005) 1.70
The Crohn's disease-associated bacterial protein I2 is a novel enteric t cell superantigen. Immunity (2001) 1.69
Thromboembolic risk of postsplenectomy thrombocytosis. Arch Surg (1978) 1.67
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Response of solid tumor cells exposed to chemotherapeutic agents in vivo: cell survival after 2- and 24-hour exposure. J Natl Cancer Inst (1973) 1.64
Metabolic aspects of the role of hyperthermia im mammalian cell inactivation and their possible relevance to cancer treatment. Cancer Res (1974) 1.62
Ligand-induced association of surface immunoglobulin with the detergent-insoluble cytoskeletal matrix of the B lymphocyte. J Immunol (1982) 1.61
Infliximab treatment of severe ankylosing spondylitis: one-year followup. Arthritis Rheum (2001) 1.58
A study of the hematologic effects of chronic low-level exposure to benzene. J Occup Med (1991) 1.57
Isometric, isotonic, and isokinetic torque variations in four muscle groups through a range of joint motion. Phys Ther (1983) 1.57
Neural correlates of attention and working memory deficits in HIV patients. Neurology (2001) 1.55
Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis (2004) 1.53
Cell survival and repair of plateau-phase cultures after chemotherapy--relevance to tumor therapy and to the in vitro screening of new agents. Cancer Chemother Rep (1974) 1.53
Lateral interactions among membrane proteins. Implications for the organization of gap junctions. Biophys J (1987) 1.52
Pathogenesis of spondylarthropathies. Persistent bacterial antigen, autoimmunity, or both? Arthritis Rheum (1995) 1.52
Assessment of acute spinal inflammation in patients with ankylosing spondylitis by magnetic resonance imaging: a comparison between contrast enhanced T1 and short tau inversion recovery (STIR) sequences. Ann Rheum Dis (2005) 1.51
Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun (2000) 1.49
Crosslinking by ligands to surface immunoglobulin triggers mobilization of intracellular 45Ca2+ in B lymphocytes. J Cell Biol (1979) 1.49
Eosinophilic fasciitis and myositis: use of imaging modalities for diagnosis and monitoring. Ann Rheum Dis (2008) 1.49
A comparison of new bone formation in patients with ankylosing spondylitis and patients with diffuse idiopathic skeletal hyperostosis: a retrospective cohort study over six years. Arthritis Rheum (2011) 1.49
Brain areas specific for attentional load in a motion-tracking task. J Cogn Neurosci (2001) 1.48
Use of dynamic magnetic resonance imaging to detect sacroiliitis in HLA-B27 positive and negative children with juvenile arthritides. J Rheumatol (1998) 1.46
Probing bulk electronic structure with hard X-ray angle-resolved photoemission. Nat Mater (2011) 1.45
Use of NSAIDs and infection with Helicobacter pylori--what does the rheumatologist need to know? Rheumatology (Oxford) (2008) 1.45
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis (2010) 1.44
Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis (2007) 1.44
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis (2007) 1.43
Thermotolerance and heat shock proteins in mammalian cells. Radiat Res (1982) 1.41
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum (2005) 1.41
Early sacroiliitis in patients with spondyloarthropathy: evaluation with dynamic gadolinium-enhanced MR imaging. Radiology (1995) 1.40
MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis (2007) 1.40
[Arthritis of the atlanto-axial joint with inflammatory neck pain as a primary manifestation of seronegative rheumatoid arthritis]. Dtsch Med Wochenschr (2010) 1.40
Reverse transcriptase template switching during reverse transcriptase-polymerase chain reaction: artificial generation of deletions in ribonucleotide reductase mRNA. J Lab Clin Med (2001) 1.39
[Value of inpatient care in rheumatoid arthritis-an evidence based report]. Z Rheumatol (2004) 1.39
[Invasive pneumonia diagnosis in community-acquired pneumonia]. Pneumologie (1996) 1.39
Direct identification of critical clusters in chemical vapor deposition. Phys Rev Lett (2006) 1.38
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology (Oxford) (2004) 1.37
Overexpanded B cell clone mediating leukemic arthritis by abundant secretion of interleukin-1beta: a case report. Arthritis Rheum (1998) 1.37
Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis (2005) 1.37
Potential for therapy of drugs and hyperthermia. Cancer Res (1979) 1.37
Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis (2005) 1.35
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
A community-wide outbreak of hepatitis A: risk factors for infection among homosexual and bisexual men. Am J Med (1995) 1.34
Ankylosing spondylitis--cardiac manifestations. Clin Exp Rheumatol (2002) 1.33
Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum (2010) 1.33
Inflammation in ankylosing spondylitis: a systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis (2004) 1.33
Gender differences in the functional organization of the brain for working memory. Neuroreport (2000) 1.33
Limited B cell repertoire in severe combined immunodeficient mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans. J Clin Invest (1991) 1.32
A proposed operational model of thermotolerance based on effects of nutrients and the initial treatment temperature. Cancer Res (1980) 1.32
[New therapeutic viewpoints on ulcus molle]. Hautarzt (1975) 1.32
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
Spontaneous redistribution of surface immunoglobulin in the motile B lymphocyte. J Exp Med (1976) 1.31
Codon 17 polymorphism of the cytotoxic T lymphocyte antigen 4 gene in Hashimoto's thyroiditis and Addison's disease. J Clin Endocrinol Metab (1997) 1.31
Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol (2002) 1.29
Anatomic structures involved in early- and late-stage sacroiliitis in spondylarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum (2003) 1.29
Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis (2001) 1.29
Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infect Immun (1999) 1.28
ASAS/WHO ICF Core Sets for ankylosing spondylitis (AS): how to classify the impact of AS on functioning and health. Ann Rheum Dis (2010) 1.28
No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis: a three-month, multicenter, double-blind, randomized, placebo-controlled study. Arthritis Rheum (1999) 1.28
Three-dimensional analysis of shear wave propagation observed by in vivo magnetic resonance elastography of the brain. Acta Biomater (2006) 1.28
Repair of potentially lethal damage in vivo in solid tumor cells after x-irradiation. Cancer Res (1974) 1.27
Measuring esophageal motility with a new intraluminal impedance device. First clinical results in reflux patients. Scand J Gastroenterol (1994) 1.27
Chromosome aberrations induced by thymidine. Exp Cell Res (1966) 1.27